MGMT and central nervous system cancer: Most importantly, the outcome of patients with gliomas was not significantly improved after treatment with O6‐BG in those clinical trials,[42, 43, 44] suggesting that the activation of the MGMT‐associated signaling pathway could compensate for the disruption of MGMT by O6‐BG.